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ABSTRACT  
   
Alzheimer's Disease (AD) is a progressive neurodegenerative disease accounting for 50-
80% of dementia cases in the country. This disease is characterized by the deposition of 
extracellular plaques occurring in regions of the brain important for cognitive function. A primary 
component of these plaques is the amyloid-beta (Aβ) protein. While a natively unfolded protein, 
Aβ can misfold and aggregate generating a variety of different species including numerous 
different soluble oligomeric species some of which are precursors to the neurofibrillary plaques.  
Various of the soluble aβ oligomeric species have been shown to be toxic to cells and 
their presence may correlate with progression of AD. Current treatment options target the 
dementia symptoms, but there is no effective cure or alternative to delay the progression of the 
disease once it occurs. Aβ aggregates show up many years before symptoms develop, so 
detection of various Aβ aggregate species has great promise as an early biomarker for AD. 
Therefore reagents that can selectively identify key early oligomeric Aβ species have value both 
as potential diagnostics for early detection of AD and as well as therapeutics that selectively 
target only the toxic Aβ aggregate species.   
 Earlier work in the lab includes development of several different single chain antibody 
fragments (scFvs) against different oligomeric Aβ species. This includes isolation of C6 scFv 
against human AD brain derived oligomeric Aβ (Kasturirangan et al., 2013). This thesis furthers 
research in this direction by improving the yields and investigating the specificity of modified C6 
scFv as a diagnostic for AD. It is motivated by experiments reporting low yields of the C6 scFv. 
 We also used the C6T scFv to characterize the variation in concentration of this particular 
oligomeric Aβ species with age in a triple transgenic AD mouse model. We also show that  C6T 
can be used to differentiate between post-mortem human AD, Parkinson's disease (PD) and 
healthy human brain samples. These results indicate that C6T has potential value as a diagnostic 
tool for early detection of AD.  
ii 
DEDICATION  
   
To Seshadri Swamigal, whose grace has helped me complete this project successfully and 
my parents - for their love and support. 
 
iii 
ACKNOWLEDGMENTS 
 I would like to place on record my heartfelt thanks to my advisor, Dr. Michael Sierks for 
his constant support and guidance through the past years. He has always been a constant source of 
inspiration and has guided me through the last few years to complete my Masters. I would like to 
say thanks for all the opportunities he provided me while working in his laboratory, which 
include numerous research projects and attending conferences. I would also like to thank Dr. 
Kaushal Rege and Dr. Christine Pauken for agreeing to serve on my thesis committee. 
 I would like to thank Dr. Sharareh Emmadi and Philip Schulz who were very helpful and 
instrumental in the completion of this project. I would also like to thank Dr. Stephanie Williams 
for helping me out with the ELISA protocol discussed in the characterization studies. My 
colleagues and lab mates Dr. Wei Xin, Dr. Patrick Yang, Huilai, Taylor, Jessica, and Vick have 
played an important role in making the  lab a fun place to work in. I not only had fun but learnt a 
lot from each and every one of you. 
 Last but not the least, I would like to thank my parents who have been very supportive 
through the years and have always believed in and encouraged me to pursue my dreams. I would 
also like to thank my brother, my role model, for being a constant source of inspiration and for 
urging me to always aim high. Thanks for being there for me. Last but not the least, I would like 
to thank my roommates for making me feel at 'home' away from home. Couldn't have done it 
without your support! 
 
 
 
 
 
 
iv 
TABLE OF CONTENTS  
          Page 
LIST OF TABLES .............................................................................................................................. vi i 
LIST OF FIGURES ............................................................................................................................ viii  
CHAPTER 
1    INTRODUCTION ...........................................................................................................  1  
1.1 Alzheimer's Disease .............................................................................................. 1  
1.2 Neuropathology and biochemical changes ..................... .....................................2  
   1.2.1 Plaques.............................................................................................3 
   1.2.2 Neurofibrillary Tangles (NFT).........................................................4 
   1.2.3 Braak staging....................................................................................4 
  1.3 AD Genetics......................................................................................................5 
   1.3.1 Apolipoprotein-E (APOE)................................................................5 
   1.3.2 Presinilin-1 and Presinilin-2.............................................................6 
   1.3.3 Amyloid precursor protein (APP).....................................................6 
  1.4 AD Pathogenesis...............................................................................................7 
   1.4.1 Cholinergic hypothesis.....................................................................7 
   1.4.2 Tau hypothesis..................................................................................8 
   1.4.3 Amyloid hypothesis..........................................................................8 
  1.5 Role of Aβ in AD............................................................................................10 
  1.6 Oligomeric Aβ-potential biomarker................................................................10 
  1.7 Targeting oligomeric Aβ.................................................................................12 
  1.8 scFv based therapeutics..................................................................................13 
  1.9 Research Objectives........................................................................................14 
 
v 
2    FRAMESHIFT CORRECTION .................................................................................... 15 
2.1 Introduction.... ..................................................................................................... 15  
2.2 Experimental procedure ................................................................................. .....16  
   2.2.1 Plasmid isolation.............................................................................16 
   2.2.2 Restriction digestion.......................................................................16 
   2.2.3 Dialysis tubing method...................................................................17 
   2.2.4 Polymerase chain reaction..............................................................17 
   2.2.5 Ligation Reaction............................................................................18 
   2.2.6 Competent cell preparation and transformation.............................18 
   2.2.7 Expression and purification of scFv...............................................19 
   2.2.8 C6 and C6T comparison.................................................................19 
   2.2.9 C6T phage production....................................................................20 
    2.2.9.1 Phage titer.......................................................................20 
  2.3 Results and Discussion...................................................................................20 
   2.3.1 Plasmid isolation and digestion......................................................20 
   2.3.2 Frameshift correction......................................................................21 
   2.3.3 C6 vs. C6T Western blot................................................................23 
   2.3.4 C6T phage production....................................................................24 
3    TISSUE CULTURE AND CHARACTERIZATION STUDIES ................................. 25  
3.1 Introduction ......................................................................................................... 25  
3.2 Experimental procedure ...................................................................................... 26  
   3.2.1 7PA2 and CHO dot blot..................................................................26 
    3.2.1.1 7PA2 and CHO cell line maintenance............................26 
    3.2.1.2 Preparation of synthetic Aβ............................................27 
    3.2.1.3 7PA2 and CHO dot blot..................................................27 
vi 
   3.2.2 AFM sample preparation................................................................28 
   3.2.3 C6T-Aβ co-incubation....................................................................28 
   3.2.4 Mouse tissue dot blot......................................................................28 
   3.2.5 C6T sandwich ELISA.....................................................................29 
    3.2.5.1 C6T scFv capture............................................................30 
    3.2.5.2 H1V2 phage biotinylation..............................................31 
    3.2.5.3 ELISA Mice sample preparation....................................31 
    3.2.5.4 ELISA Human sample preparation.................................32 
    3.2.5.5 ELISA protocol...............................................................32 
  3.3 Results and Discussion...................................................................................32 
   3.3.1 7PA2 and CHO dot blot assay........................................................32 
   3.3.2 AFM Imaging.................................................................................34 
   3.3.3 Aβ-C6T co-incubation....................................................................35 
   3.3.4 Mouse tissue dot blot......................................................................37 
   3.3.5 C6T Sandwich ELISA....................................................................38 
    3.3.5.1 C6T scFv capture ELISA...............................................38 
    3.3.5.2 H1V2 phage biotinylation.............................................39 
    3.3.5.3 Mouse ELISA.................................................................40 
    3.3.5.4 Human ELISA................................................................41 
4    CONCLUSION ..........................................................................................................  ...43  
Summary ................................................................................................................... 43  
Future work ............................................................................................................... 44  
REFERENCES  ...................................................................................................................................  45 
vii 
LIST OF TABLES 
Table   Page 
2.1      Restriction digestion of C6T.......................................................................... ...............16 
2.2      PCR reaction setup........................................................................................................ 17 
2.3      Corrected C6T DNA sequence..................................................................................... 22 
           3.1      BCA assay-mice samples for dot blot.......................................................................29 
           3.2      BCA assay-mice samples for ELISA........................................................................31 
           3.3      C6T scFv on ELISA..................................................................................................38 
           3.4      H1V2 phage biotinylation.........................................................................................39 
           3.5      ELISA mice sample analysis....................................................................................40 
           3.6      ELISA human sample analysis.................................................................................42 
 
 
 
 
viii 
LIST OF FIGURES 
       Figure Page 
1.1       Plaques and NFTs in Alzheimer's brain ........................................................................  1 
1.2       Healthy vs. Alzheimer's brain .......................................................................................  3 
1.3       Braak stages ...................................................................................................................  5 
           1.4      APP processing...........................................................................................................9  
           1.5      Amyloid cascade hypothesis.....................................................................................11 
           1.6      Aggregation of Aβ....................................................................................................12 
           1.7      scFv representation...................................................................................................13 
           2.1      C6 frameshift mutation.............................................................................................15 
           2.2      Ni bead scFv extraction............................................................................................19 
           2.3      Cut C6 plasmid on 2% agarose gel...........................................................................21 
           2.4      C6T scFv production.................................................................................................23 
           2.5      C6 vs. C6T production..............................................................................................24 
           3.1      Atomic force microscopy (AFM) principle..............................................................26 
           3.2      C6T Sandwich ELISA..............................................................................................30 
           3.3      7PA2 and CHO dot blot with 6E10 primary.............................................................33 
           3.4      7PA2 and CHO dot blot with C6T scFv...................................................................34 
           3.5      AFM images of 7PA2 and CHO with C6T phage....................................................35 
           3.6      C6T-Aβ co-incubation..............................................................................................36 
           3.7      Mouse dot blot..........................................................................................................37 
           3.8      ImageJ analysis of mouse dot blot............................................................................37 
           3.9      C6T ELISA with mice samples................................................................................41 
1 
 
Chapter 1 
INTRODUCTION 
1.1 Alzheimer's disease: 
Alzheimer's disease (AD) is a progressive neurodegenerative disease accounting for 50-80% of 
dementia cases and is the 6th leading cause of death in the country (“Alzheimer’s disease,” n.d.). 
AD is characterized by deposition of extracellular amyloid-beta (Aβ) plaques and intracellular 
neurofibrillary tangles (NFT) in the brains of AD patients (Figure 1.1). There is extensive 
neuronal cell death and loss of neuronal interactions in regions of the brain important for 
cognition. This leads to brain atrophy affecting the patient's ability to comprehend, think and 
form new memories.  
 
Figure 1.1: An artist's impression of a healthy and AD brain section with the occurrence of 
amyloid plaques and neurofibrillary tangles (www.ahaf.org/alzheimers) 
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Current drugs try to improve the general condition of the patients by treating their behavioral and 
cognitive symptoms. Drugs like Donepezil and Rivastigmine are cholinesterase inhibitors and are 
commonly prescribed to treat cognitive deficits (Bond et al., 2012). Memantine is another drug 
commonly prescribed that regulates glutamate, a chemical messenger involved in memory and 
learning. Although these drugs can't reverse disease progression, they help reduce the symptoms 
and stabilize the condition over a small period of time. Unfortunately, there is no effective 
therapy to cure or slow down the progression of the disease once it occurs.  
AD not only affects patients but also takes its toll on immediate family, friends and caregivers. As 
the disease progresses, significant demands are placed on care givers, resulting in increased 
stress, physical exhaustion and emotional drain. Caregivers of patients with AD and other 
dementias face additional health care costs of their own. These factors stress the importance of 
understanding the underlying mechanism of AD to design better treatment options.  
1.2 Neuropathology and biochemical changes: 
Although AD has characteristic clinical features which include memory loss and behavioral 
changes like depression and irritability, a neuropathological examination of the diseased brain is 
required for a definitive diagnosis to distinguish it from other dementias. Microscopic changes in 
the brain occur much earlier than the clinical symptoms. Pathological examination of AD brain 
shows shrinkage in the size of the brain particularly the hippocampus and the medial temporal 
lobes (Figure 1.2). Quantitative studies of neurons have shown considerable neuronal loss in the 
neocortex, hippocampus, locus coeruleus and other regions of the brain (West, Coleman, Flood, 
& Troncoso, 1994)(Terry, 1981). Characteristic pathological features of AD includes the 
occurrence of plaques and neurofibrillary tangles. Braak staging is used to define these features as 
the disease progresses. 
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Figure 1.2: Shrinkage of cerebral cortex and hippocampus associated with AD compared to 
healthy brain (www.nia.nih.gov/alzheimers). 
 1.2.1 Plaques. Extensive amyloid plaques are a characteristic feature of AD and vary in 
size between 5-200mm. Previous studies have shown that the amyloid plaque core from AD brain 
is similar to the amyloid found in Down's syndrome patients (Masters, Multhaup, Simms, 
Martins, & Beyreuther, 1985). It was also shown that amyloid in these plaques is actually cleaved 
from a larger precursor protein called the amyloid precursor protein (Weidemann et al., 1989).  
Plaques have an amyloid core with aggregates forming β pleated sheets. They can be classified as 
neuritic plaques, plaques surrounded by degenerate neurites, and diffuse plaques based on  
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differences in their structure. The diffuse plaques do not take up congo red stain and have Aβ (1-
42) as its main component which is similar to Down's syndrome. An anti-Aβ antibody can be 
used to visualize the different plaques in immunocytochemistry. The neuritic plaques on the other 
hand, have a defined central core structure which take up the stain. Its main component is a 
shorter Aβ (1-40). Diffuse plaques are found commonly in the cerebellum while both diffuse and 
neuritic plaques occur together in other regions of the brain (Joachim, Morris, & Selkoe, 1989). 
The exact nature of plaque formation is not clear. It could be due to irregular processing of APP, 
or improper metabolization of Aβ which disrupts its clearance in the brain and causes its 
accumulation. Even though amyloid plaques occur in the process of normal aging and in other 
neurodegenrative diseases, its occurrence in AD is relatively high which makes it one of the 
defining features of AD (Tomlinson, Blessed, & Roth, 1997)(Perry et al., 1978).  
 1.2.2 Neurofibrillary tangles (NFT). Neurofibrillary tangles are intraneuronal structures 
whose primary component is hyperphosphorylated tau (Iy, Wu, Smith, Grundke-iqbal, & Y, 
1998). It is one of the key features of AD following plaque formation. Tau is a microtubule 
associated protein helping in microtubule formation and stabilization. However in AD, the 
hyperphosphorylated tau can no longer bind to the microtubules and start clumping together (Lee 
et al., 2005). This, eventually, leads to the formation of NFT. The size of the NFTs depends on 
the neuron size with some of the largest typically found in the locus coeruleus. Neuropil threads 
are linear structures consisting of dendrites of neurons with NFT (Islands, 1986).They can be 
easily visualized using thioflavin or silver staining.  
 1.2.3 Braak staging. Braak staging is a technique used to describe the number of tau 
tangles present in the brain by defining six different stages as shown in Figure 1.3 (Braak & 
Braak, 1991).  
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Figure 1.3: Braak stages of tau tangle formation in AD. (Adapted from 
www.nia.nih.gov/alzheimers).  
Stage I and II is characterized by the presence of hyperphosphorylated tau in the transentorhinal 
region with the occurrence of a few tangles between the cortex and hippocampus. There are no 
obvious signs of memory impairment with minor mood and personality changes. 
There is extensive neuronal cell death in the hippocampus in stages III and IV with tangles 
beginning to form in the neocortex of the brain. Patients in these stages are diagnosed with 
dementia and experience hallucinations accompanied by changes in behavior such as frequent 
irritability, anger and a loss of self-awareness. Patients in stage V and VI are classified with 
severe dementia. They have trouble taking care of themselves and require constant supervision 
for day-to-day activities.  
1.3 AD Genetics: 
The onset of AD is largely sporadic with certain mutations and environmental factors playing a 
crucial role.  0.1% of the cases, on the other hand, are familial and lead to early onset of familial 
Alzheimer's Disease (FAD) (Blennow, De Leon, & Zetterberg, 2006). Studying the genetics 
involved in AD helps us understand risk factors involved. Mutations in APP, presenilin-1 and 
presenilin-2 (PS1 and PS2) are associated with FAD while the APOE gene has been implicated in 
genetic linkage studies for late onset Alzheimer's (Ganzer et al., 2003).  
 1.3.1 Apolipoprotein-E (APOE). Genetic linkage studies have shown APOE to be a 
major risk factor in the late onset, sporadic form of AD (Ganzer et al., 2003)(Schmechel et al.,  
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1993). The APOE gene is located on chromosome 19q13.2, and codes for a protein (317 residues 
long) responsible for binding, internalization and catabolism of lipoprotein particles. APOE is 
synthesized by glial cells in the brain and has three common isoforms: APOE2, APOE3 and 
APOE4. Studies have shown that APOE interacts with Aβ by catalyzing its breakdown both 
within and outside the cell (Wisniewski, Frangione, 1992). The E4 allele however is not as 
effective as the rest in this process. This makes individuals carrying the APOE4 allele more 
susceptible to AD (Jiang et al., 2008).  
 1.3.2 Presenilin-1 and Presenilin-2. The PS1 gene is located on chromosome 14q24.2 
and PS2 is located on chromosome 1q42.13. These genes have been shown to be associated with 
FAD (St George-Hyslop, 1995)(Levy-lahad et al., 2013). PS2 encodes a 448 amino acid 
polypeptide that has a 67% homology with PS1. Both of these have distinct but overlapping γ-
secretase activity which is involved APP processing (Kopcho et al., 2003). It has been shown that 
presenilin forms the catalytic core of the γ-secretase that interacts with APP (Schroeter et al., 
2003).  
Studies have shown that mutations in the PS1 leads to an increased Aβ-42 to Aβ-40 ratio 
resulting in occurrence of AD in the 26-60years age group (Gustafson et al., 1998)(Jonghe et al., 
1999) while mutations in PS2 lead to onset of AD in the 40-75 year age group. About 130 
mutations in PS1 have been identified with FAD compared to PS2, which is not as common. 
 1.3.3 Amyloid precursor protein (APP). APP gene is located on chromosome 21q21.2 
and codes for an integral membrane protein expressed in most tissues. It has seven known 
alternate transcripts of which APP695 is expressed in neurons while APP770 transcript is 
expressed in other tissues. The exact role of APP is not clear although it has been implicated in  
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synpase formation and neural plasticity (Priller et al., 2006)(Turner, O’Connor, Tate, & Abraham, 
2003).  
Mutations in APP have been associated with FAD (Owen & Hardy, 1991). β and γ-secretase 
enzymes are responsible for the cleavage of APP resulting in toxic Aβ species. Most of the 
mutations in APP occur near the β-secretase site, which results in an overall increase in the toxic 
Aβ species without a change in the Aβ40/Aβ42 ratio. However mutations in the γ-secretase site 
leads to an increase in the Aβ40/Aβ42 ratio (Citron & Oltersdorf, 1992)(De Strooper & Annaert, 
2000). Understanding the genetic component of AD helps in understanding the transmission and 
the risk factors associated with it. However a systematic, multi-pronged approach is required to 
understand its etiology.  
1.4 AD pathogenesis: 
There are three major hypotheses that try to explain the hallmarks of AD and the underlying 
disease mechanism. They are the cholinergic hypothesis, amyloid hypothesis and the tau 
hypothesis.  
 1.4.1 Cholinergic hypothesis. Cholinergic is one of the oldest hypotheses proposed for 
AD. The cholinergic hypothesis states that AD is caused by the reduced synthesis of the 
neurotransmitter acetylcholine. Here, the loss of cholinergic neurons and associated factors relate 
better with preclinical symptoms like memory loss (P. Davies & Maloney, 1976)(Bartus, Dean, 
Beer, & Lippa, 1982). Although there is Aβ accumulation in the brains of AD leading to senile 
plaques, neuronal loss and changes in neurotransmitter levels correlate better with disease 
progression. Studies show that while cholinergic, seratonergic and glutamatergic deficits exist, 
other catecholamine, GABAergic and somatostatin neurons remain unaffected in moderate AD 
(Fracis & Bowen, 1993)(P. H. Davies, Stewart, Lancranjan, Sheppard, & Stewart, 1998).  
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The initial medications for Alzheimer's, based on this hypothesis was to preserve the 
neurotransmitter acetylcholine by inhibiting the acetylcholinesterases. Although these drugs treat 
only the symptoms of the disease and can't reverse the condition, they provide temporary relief 
from memory loss symptoms. It is possible that the acetylcholine deficiencies observed might be 
a result of widespread brain tissue damage. 
 1.4.2 Tau hypothesis. There are two proteins that misfold and aggregate in AD: Aβ and 
the tau protein leading to the formation of plaques and tangles. The tau hypothesis states that the 
neurotoxicity in AD brains is due to the occurrence of hyperphosphorylated tau. The 
hyperphosphorylated tau aggregates to form paired helical filaments (PHF), twisted ribbons and 
straight filaments (SF) (Iy et al., 1998)(Lee et al., 2005). This results in microtubule dissociation 
which affects the internal transport network of the neuron eventually leading to neuronal loss 
(Alonso, Zaidi, Grundke-Iqbal, & Iqbal, 1994). Although Aβ formation is thought to play a role 
in tau hyper-phosphorylation (Zheng, Bastianetto, Mennicken, Ma, & Kar, 2002)  their exact 
relationship and role in AD is not clear.   
 1.4.3 Amyloid hypothesis. A major component of the neuritic plaques in AD is the Aβ 
protein which was isolated and sequenced followed by the isolation and sequencing of APP from 
which it is generated(Glenner & Wong, 1984)(Masters et al., 1985). According to the amyloid 
hypothesis, the formation of Aβ peptide and its aggregation is responsible for the AD pathology.  
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Figure 1.4: Proteolytic processing pathway of amyloid precursor protein (APP). 
APP is proteolytically cleaved via two major pathways: the non-amyloidogenic and 
amyloidogenic pathways as shown in Figure 1.4 (Selkoe, 1994). In normal cell types, APP is first 
cleaved by α-secretase releasing sαAPP, important for neuronal growth and survival. It remains 
within the neuron and interacts with nucleus factors. The APP is then cleaved by γ-secretase 
which releases the smaller fragment outside of the neuron.  
In the amyloidogenic pathway, APP is cleaved by β-secretase followed by γ-secretase leading to 
the release of sticky Aβ fragment outside of the neuron (Haniu et al., 2000). Several such 
fragments that are not cleared from the brain clump together extracellularly, leading to the 
formation of protofibrils, fibrils and eventually plaques in AD brains. 
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1.5 Role of Aβ in AD: 
As mentioned in the previous section, Aβ is a 4kDa peptide generated by the cleavage of APP in 
the by β and γ-secretase sites. The γ-secretase cut generates peptides of varying lengths (36-43 
residues) and includes Aβ40Aβ and Aβ42Aβ, which are commonly found in AD. The exact role 
of Aβ is not clear although it has been implicated in protection against oxidative stress, as a 
trascription factor and in the activation of kinases (Zou, Gong, Yanagisawa, & Michikawa, 
2002)(Tabaton, Zhu, Perry, Smith, & Giliberto, 2011)(Bailey & Maloney, 2012). Occurrence of 
Aβ40Aβ is more common, while fibrillogenic Aβ42Aβ is associated with the diseased state 
(Jarrett, Berger, & Lansbury, 1993).  
Aβ42Aβ is hydrophobic by nature and is insoluble in water allowing it to readily aggregate to 
form plaques in AD (Barrow & Zagorski, 1991). Certain mutations or defects as discussed in the 
previous section, cause an overall increase in Aβ production and/or decreased Aβ clearance. 
When the sensitive balance between Aβ production and clearance is disrupted, it leads to Aβ 
aggregation.  
Fibrillar Aβ can be visualized via immunostaining using specific anti-Aβ antibodies. Congo red 
has also been used extensively and has been shown to bind to the β sheet structure in fibrillar Aβ 
(Klunk, Jacob, & Mason, 1999). Positron emission tomography (PET) technique combined with 
the selective binding of Pittsburg compound B (PIB) to fibrillar Aβ has been successfully used for 
imaging as well. Atomic force microscopy can also be used to observe features of Aβ at the 
nanoscale level.  
1.6 Oligomeric Aβ-potential biomarker: 
In the process of fibril and plaque formation different conformations of intermediate soluble Aβ 
oligomers have been identified from brain, plasma and CSF (Lambert et al., 1998)(Harper,  
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Lansbury, Wong, & Lieber, 1996) (Emmerling, 1996). Although historically Aβ plaques were 
thought to play a major role in AD, the modified amyloid hypothesis (Figure 1.5) suggests that 
the soluble oligomeric Aβ intermediates are the actual toxic species in AD (Lambert et al., 2001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Outline of amyloid cascade hypothesis (Pangalos, Jacobsen, & Reinhart, 2005).  
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These oligomers have been shown to be synapto-toxic leading to disruption of synaptic plasticity 
(Shankar et al., 2009). Studies have also shown that these species correlate better with neuronal 
loss and deficits in memory compared to plaque deposits (Francisco, Jolla, Pharmaceuticals, & 
San, 1999)(Näslund et al., 2013). 
Studies show that different oligomers permeabilize cell membranes, assemble into lipid bilayers 
(Bucciantini et al., 2002) and localize in lipid rafts, regions rich in cholesterol and 
glycosphingolipids (Simons & Toomre, 2000). Aβ largely resides in lipid rafts in the brain 
(Morishima-kawashima & Ihara, 1998) and it is possible that these lipid rafts provide the right 
environment for the oligomerization of Aβ.  
1.7 Targeting oligomeric Aβ:  
Aggregation of Aβ follows a sigmoid curve with characteristic lag, log and saturation phase. Aβ 
nucleation seeds are generated in the initial lag phase.  
  
 
 
 
 
 
 
 
 
Figure 1.6: Aggregation of Aβ from monomer to fibrils follows a sigmoid curve with a lag, 
growth and saturation phase. 
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This is followed by the elongation step where oligomeric Aβ further aggregate to form fibrils. 
However there are some oligomers that might be off the pathway and don't lead to fibril 
formation. Studies show that oligomeric Aβ are the synapto-toxic species in AD pathogenesis and 
are potential targets for developing therapeutics. Compounds like cholyl amide PPI-368 and PPI-
3019 have shown to delay Aβ nucleation in-vitro (Wolfe, Esler, & Das, 2002). Although 
immunization with aggregated Aβ delayed its deposition and cleared away existing Aβ in mice 
(Schenk et al., 1999)(Bard et al., 2000), side effects like meningoencephalitis were experienced in 
the human trial (Delrieu, Ousset, Caillaud, & Vellas, 2012). Despite the recent Aβ immunization 
trials in humans, targeting oligomeric Aβ holds considerable promise.  
1.8 scFv based therapeutics: 
While current immunization trials with full-length antibodies targeting Aβ have been successful 
in reducing the Aβ plaques, unless the inflammatory side effects are overcome, it cannot become 
a potential therapeutic. Passive immunization with scFv however holds considerable promise over 
the traditional monoclonal antibody since it is much smaller in size and can easily penetrate 
tumors (Yokota, Milenic, Whitlow, & Schlom, 1992).  
 
 
 
 
 
 
 
Figure 1.7: Schematic representation of a single chain variable fragment (scFv). 
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In other words, the scFv retains the antigen binding domains of its parent antibody while its small 
size allows easier tissue penetration. scFv uptake by the kidney is usually low and its rapid 
clearance from blood make it a favorable reagent for use in therapeutics (Kim et al., 2002). 
Phage display scFv has several other advantages over using a full-length antibody. They can be 
rapidly produced in E. coli, yeast and a variety of other hosts and can be manipulated with great 
ease to therapeutic needs. They are potential interventional agents and have been used in a 
number of diseases like cancer (Arafat, Gomez-Navarro, & Xiang, 2002). Therefore diagnostic 
and therapeutic strategies involving scFv hold great promise for AD. 
1.9 Research Objectives:  
As discussed above, there is need for an anti-oligomeric Aβ for diagnostic and therapeutic 
purposes in AD. With these motivations in mind, this thesis presents characterization of an anti-
oligomeric C6 scFv, isolated against human brain derived oligomeric Aβ Kasturirangan et al., 
(2013).  
The research objectives include: 
1) Identifying and rectifying the cause for low scFv yields: frameshift mutation. 
2) Characterizing the fixed C6'T' clone using 7PA2 cell line over expressing Aβ oligomers.  
3) C6T as a diagnostic tool: Characterizing AD mouse and human post-mortem tissue 
samples. 
This thesis consists of four parts, where chapter 2 deals with the occurrence of frameshift 
mutation in the C6 sequence and its correction. Chapter 3 presents detailed characterization 
studies of the fixed C6T clone with homogenized AD mice and human brain tissue samples. 
Chapter 4 provides an overall summary of the work and recommended future directions. 
15 
 
Chapter 2 
FRAMESHIFT CORRECTION 
2.1 Introduction: 
Antibodies with high affinity and specificity are great tools for diagnostics and therapeutics. 
Hybridoma technology is a long and laborious process that involves antigen specific 
immunization before a monoclonal antibody (mAb) can be obtained. The Sheets library, on the 
other hand, utilizes phage display technology to express human scFv on the phage coat protein. 
The scFv expressed consists of the VH and VL antigen binding domains connected by a peptide 
linker chain. The library has a concentration of 10
12
 pfu/mL which can be efficiently used to 
isolate scFv's against specific antigens (Dierich et al., 1998).  
Previous work in our lab includes isolation of C6 scFv from the Sheets library against natural 
brain-derived Aβ oligomers from Sheets library. Kasturirangan et al,. performed several rounds of 
negative panning to get rid of the non-specific binders followed by a positive round against 
natural brain-derived Aβ oligomers to isolate the C6 clone. C6 scFv produced had issues with 
expression and protein was obtained in only low quantities. 
 
 
 
 
Figure 2.1: C6 sequence with frameshift mutation 
Upon sequencing the C6 clone it was observed that a frameshift (deletion) mutation occurred at 
the amino terminal as seen in Figure 2.1. It is not clear how a clone with a deletion mutation  
NcoI C6 insert His c-myc NotI Frameshift 
GCCATGGCCCAGGTACAGCTGCAGGAGTC_GGGGGAGGCTTGGTACAG
CCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTT 
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produces scFv. There are two possibilities: 1) A ribosomal frameshift further down the sequence 
complements the initial deletion mutation allowing the sequence to be read correctly, 2) The 
occurrence of a translational frameshift where the frame in which the ribosome reads the 
sequence is altered. Here we describe how the frameshift mutation was corrected using specific 
PCR primers, designed to insert the missing nucleotide and increase scFv production.  
2.2 Experimental procedure: 
 2.2.1 Plasmid isolation. The C6 scFv is in the pIT2 vector plasmid, the most common 
plasmid vector used for expression purposes in the host E. coli strain HB2151. 5mL of C6 
culture was grown overnight in the 37°C shaker and the plasmid was isolated using a plasmid 
mini-prep kit (Qiagen, Valencia, CA).  
 2.2.2 Restriction digestion. Restriction enzymes are 'molecular scissors' capable of 
recognizing specific nucleotide sequences, cleaving it at or near these restriction sites.  
Reagent Volume (µL) 
NEB Buffer 5.0 
BSA 0.5 
NcoI 2.0 
NotI 2.0 
Plasmid sample 30.0 
Water 10.5 
Table 2.1: Restriction digestion of C6 plasmid to obtain the C6 scFv sequence 
The restriction enzymes NcoI (restriction site: 5' C*CATGG 3')  and NotI (restriction site: 5' 
GC*GGCCGC 3')  were used to cut out the original C6 sequence (Table 2.1) with the frameshift 
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mutation and His tag out of the pIT2 plasmid. The digestion reaction was verified by running the 
samples on a 2% agarose gel. 
 2.2.3 Dialysis tubing method. The bands from the gel were cut and frozen at -20°C. The 
frozen gel slices were then placed into a dialysis tubing with 200-400µL of 1X TAE buffer. The 
gel slice with the bands were then placed parallel to the electrodes in an electrophoretic tank and 
a voltage of 100V/cm was applied for 10 min. The buffer was removed from the dialysis tube and 
phenol-chloroform extraction was performed on it. The yields on it were in the range of a few 
ng/µL. Traditional spin columns from gel extraction kit (Qiagen, Valencia) was also used to 
extract the cut plasmid from the gel slices.  
 2.2.4 Polymerase chain reaction. PCR was performed on the C6 fragment with primers 
specifically designed to fix the deletion present ~26 bases downstream from the start codon.  
Reagent Volume (µL) 
Water 36 
10µM DNTP 1 
5X Buffer 10 
GoTaq Polymerase 0.5 
Primer 1 1 
Primer 2 1 
Template 0.5 
Table 2.2: PCR reaction setup to fix frameshift mutation 
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The primers were designed to insert the missing 'T'  nucleotide. The primers are about 48 
nucleotides long and the forward primer allows the addition of the missing nucleotide that puts 
the sequence back in frame.  
5’-GCCGGCCATGGCCCAGGTACAGCTGCAGGAGTCTGGGGGAGG CTTGGT-3’  
5’-CCCGTGATGGTGATGATGATGTGCGGCCGCACGTTTGATCTCCAG -3’ 
The above primers were used to carry out the PCR reaction in the thermocycler (Table 2.2). After 
the PCR reaction was complete, the PCR products were run on 2% agarose gel to verify the 
molecular size of the products.  
 2.2.5 Ligation Reaction. The C6 PCR fragment was allowed to ligate with the cut pIT2 
plasmid in an insert to vector ratio of 3:1, 10:1 and 20:1 to have a higher chance of incorporation 
of the insert into the plasmid. Calf intestinal protease (CIP) was used during the ligation process 
to prevent the plasmid from re-ligating at the cut sites. CIP works by catalyzing the removal of 
phosphate groups from the 5' end of the DNA sequence. Ligation reaction was carried out at 37°C 
overnight.  
 2.2.6 Competent cell preparation and transformation. Competent HB2151 cells were 
prepared and 100µL of these cells were used for transformation. The ligated plasmid (with C6 
PCR insert) was added to the competent cells.  Cut pIT2 plasmid (without insert) and pLB 
plasmid were used as a negative and positive control respectively. The tubes were placed in a 
water bath at 42°C for 2 min and then placed on ice for 2 min before the addition of 800µL of LB 
media. The tubes were then incubated in the 37°C shaker for 1 hour. 100µL of cells were plated 
onto LBA plates and left at 37°C overnight. Colonies were picked out of the plates the next day 
and re-streaked. Plasmid was isolated from the re-streaked colonies and sequence verified.  
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2.2.7 Expression and purification of scFv: 100 mL of LBA was inoculated with the C6T clone 
and allowed to grow at 37°C overnight. 1:100 of the overnight culture was innoculated into 1L 
of 2xyT (containing 1% glucose) and allowed to grow till OD reached 0.8 at 600nm.  
 
Figure 2.2: Ni bead extraction of C6T scFv. 
The supernatant and periplasmic fractions were concentrated down using a tangential flow filter 
with a 10kDa membrane (Millipore). 1mL of Ni-NTA beads were added to 50mL of the 
concentrated fractions. Elution of scFv is based on Immobilized metal affinity chromatography 
(IMAC). The scFv is bound to the Ni-NTA beads via the 6X-His tag while other non specific, 
unbound proteins flow through the gravity column. The scFv was then eluted from the beads by 
using an imidazole gradient (Figure 2.2). Imidazole was removed by dialyzing the various 
imidazole fractions into 1X PBS. The purity of the scFv was tested by running a SDS-PAGE gel.  
 2.2.8 C6 and C6T comparison. C6 and C6T in pIT2 plasmid in HB2151 strain of E. 
coli was grown in 10 mL of 2xyT with ampicillin overnight at 37°C. 2mL of overnight stock 
was innoculated into 200mL of autoclaved 2xyT with ampicillin and 1% glucose. The culture 
was allowed to grow for 2-3 hours till the OD reached 0.4-0.6 at 600nm in the 
spectrophotometer. The culture was spun down and the supernatant and periplasm was  
Flow 
through 
Purified C6T 
C6T bound 
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Impurities 
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concentrated down using a 10kDa membrane (Millipore). Ni beads were used to extract scFv 
using an imidazole gradient. scFv was purified by dialyzing these fractions in 1X PBS. These 
fractions were run on SDS-PAGE gel and western blot was analyzed.  
 2.2.9 C6T phage production. The pIT2 plasmid from the fixed C6T clone was 
transformed into competent E. coli TG1 strain used for making phage. 1L of the culture was 
grown and the supernatant was treated with polyethylene glycol (PEG) and NaCl. PEG absorbs 
water and causes the phage to aggregate and precipitate as a pellet. The pellet was re-suspended 
in PBS and spun down to remove the cell debris. Phage in the supernatant was aliquoted.  
 2.2.9.1 Phage titer. TG1 cells were grown in LB till they reached an OD of 0.4-0.6 at 
600nm. TG1 was also grown in LBA media as a control to check for contamination. Different 
aliquots of the phage stock were made ranging from 10
-2
, 10
-4
, 10
-6
...10-12. 10µL of different 
phage dilutions were added to 200µL of TG1 cells and allowed to infect at 37°C for 30 min. The 
cells were plated on LB plates along with control TG1 cells on LB and LBA plates. The phage 
concentration can be calculated as follows: 
Concentration (pfu/mL) = (Number of colonies/Volume of phage) * 10
3
µL/1mL * Dilution 
factor 
Number of colonies on the plate were counted and the stock phage concentration was 
determined using the above calculation. 
2.3 Results and Discussion: 
 2.3.1 Plasmid isolation and digestion. To fix the frameshift mutation in C6T DNA 
sequence, the C6 plasmid pIT2 was isolated using a plasmid mini-prep kit with yields of 
~200ng/µL. Figure 2.3 shows the successful digestion of the C6 plasmid using NcoI and NotI 
enzymes which yielded the C6 scFv fragment (800bp) and the cut pIT2 plasmid (4kbps) in size. 
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Figure 2.3: 2% agarose gel; lane 1 and 2: cut pIT2 plasmid without insert (~4 kbps), lane 3 and 4: 
cut C6 fragment (~800bp). 
The samples were run on a 2% agarose gel to verify the digestion of the plasmid. The bands 
corresponding to C6 were cut from the gel and DNA was extracted using a gel extraction kit.  
 2.3.2 Frameshift correction. On analyzing the C6 sequence, we observed a missing 'T' 
nucleotide ~26 bases downstream of the start codon. We performed a PCR reaction with primers 
designed specifically to insert the missing 'T' nucleotide in the C6 sequence.  The primers anneal 
to the template DNA sequence in the annealing step of PCR and Taq polymerase starts adding 
nucleotides complementary to the template DNA strand in the 5'to 3' direction. To check if PCR 
worked on the C6 sequence, a 2% agarose gel was run. A gel extraction and PCR reaction 
cleanup (Qiagen, Valencia) was performed on the PCR products to remove excess primers, Taq 
polymerase and other salts in the reaction mixture.  
 
cut pIT2 plasmid 
cut C6 fragment 
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Although the agarose gel can show the amplification of C6 template, addition or changes in a 
single nucleotide cannot be observed. Hence a ligation reaction was set up with different ratios of 
the amplified C6 insert to the pIT2 plasmid. The ligated samples were transformed into 
competent HB2151 cells and spread on LBA plates. The colonies from the plates were grown and 
a plasmid prep was carried out. Sequencing on the plasmid returned a corrected sequence with the 
addition of the missing 'T' nucleotide (Table 2.3). 
C6T DNA Translated sequence 
5'GCCATGGCCCAGGTACAGCTGCAGGAGTCTGG
GGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAG
ACTCTCCTGTGCAGCCTCTGGATTCACCTTT 3' 
 
MetAQVQLQESGGGLVQP
GGSLRLSCAASGFTF 
Table 2.3: C6T DNA sequence and its translated sequence in the correct reading frame after 
fixing the upstream frameshift mutation. 
It is important to know if the fixed C6T clone produces scFv of the right molecular size (29kDa). 
This would indicate that correcting the frameshift fixed expression issues with the original C6 
clone. Hence 1L batches of the fixed C6T clone were grown in 2xyT media. The culture was spun 
down and the supernatant and the periplasm were kept separate and concentrated down to 50mL 
using a tangential filter flow with a 10kDa membrane (Millipore). In order to purify the scFv, Ni-
NTA beads were used to bind His tag in C6T while other proteins were removed through 
repetitive washes in the gravity separation columns. The bound scFv was eluted using an 
imidazole gradient. The fractions were then dialyzed in 1X PBS to get rid of any imidazole. 
Samples were run on SDS-PAGE to check for their molecular weight as shown in Figure 2.4. The 
results show strong bands corresponding to 29kDa in both the supernatant and periplasmic 
fractions. This indicates that the fixed C6T clone was able to strongly express scFv. 
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Figure 2.4: Lane 1-4: 50mM, 100mM, 200mM and 1M imidazole fractions of C6T supernatant; 
Lane 5: Supernatant flow through after removal of Ni beads; Lane 6: C6T supernatant initial 
retentate; Lane 6: C6T wash; Lane 7: 50mM imidazole fraction of C6T periplasm; Lane 8: 
Molecular weight marker; Lane 9-11: 100mM, 200mM and 1M imidazole fractions of C6T 
periplasm; Lane 12: Periplasm flow through after removal of Ni beads; Lane 13: C6T periplasm 
retentate; Lane 14: C6T wash 
 2.3.3 C6 vs. C6T Western blot. The original C6 and the fixed C6T samples were run on 
SDS-PAGE to compare differences in levels of scFv produced. Samples were loaded onto each 
well and SDS-PAGE was carried out. The gel was transferred to a nitrocellulose membrane and 
probed with anti c-myc (9E10) antibody followed by GAM. DAB staining revealed that C6T 
fractions have distinctly higher expression levels compared to the original C6 clone as seen in 
Figure 2.5. This shows that correcting the frameshift mutation fixed issues with scFv production. 
The scFv expresses well in C6T compared to the original C6 clone.  
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Figure 2.5: Lane 1: C6 supernatant flow through after removal of Ni beads; Lane 2-5: 50mM, 
100mM, 200mM and 1M imidazole fractions of C6; Lane 6: Molecular weight marker; Lane 7: 
C6T supernatant flow through after removal of Ni beads; Lane 8-11: 50mM, 100mM, 200mM 
and 1M imidazole fractions of C6T; Lane 12: anti-pLB positive control. 
 2.3.4 C6T phage production.  Characterization studies using AFM utilizes C6T phage. 
High salt/polyethylene glycol (PEG) could interfere with the imaging process (discussed in detail 
in Chapter 3). Hence it is essential to produce phage with a  high concentration and low salt/PEG 
content. C6T plasmid was transformed into TG1 strain to produce phage followed by additional 
desalting steps to get rid of the salts. Number of colonies on the LB plates were counted to 
determine the concentration of the C6T phage. C6T phage produced had a concentration of 
3.4*10
12
 pfu/mL and was used to characterize the clone as discussed in the following chapter.  
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Chapter 3 
TISSUE CULTURE AND CHARACTERIZATION STUDIES 
3.1 Introduction: 
Once the sequence of the C6T clone was corrected, we could obtain enough protein to 
characterize presence of the oligomeric Aβ target in different tissue samples.  Amyloid precursor 
protein (APP) is an integral membrane protein, whose exact function is unknown, though it has 
been shown to have a role in synaptic formation, repair and neural plasticity (Walsh et al., 2007). 
Consecutive cleavage of APP by beta-site amyloid precursor protein cleaving enzyme-1 (BACE-
1) and γ-secretase results in the generation of Aβ while α-secretase cleavage of APP hydrolyzes 
the protein in what would be the middle of the Aβ peptide, precluding its formation.C6T clone 
obtained from the Sheets library was selected against brain derived oligomeric Aβ. In order to test 
the specificity of the C6T clone, an in-vitro cell line model, 7PA2, was used. 7PA2 is a Chinese 
hamster ovarian (CHO) cell line that over expresses mutant human amyloid precursor protein 
(APP) generating excess Aβ, a fraction of which forms an SDS-stable oligomeric Aβ species. Aβ 
Atomic force microscopy (AFM), western and dot blots were used to characterize whether the 
C6T clone could react selectively with the SDS stable oligomeric Aβ produced by 7PA2 cells. 
AFM is a type of scanning probe microscopy (SPM) that allows surface visualization by 
means of an oscillating cantilever probe that scans across the surface. Whenever the tip is brought 
within close proximity of the surface to be scanned, the cantilever gets deflected which is 
recorded (Figure 3.1). It is based on the principle of Hooke's law and has a resolution in the order 
of several nanometers.  
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Figure 3.1: Principle of AFM - Cantilever probe scans across the surface and the forces between 
the tip and the surface is recorded. 
Once we verified that the C6T scFv selectively bound a cell derived oligomeric Aβ species, we 
used the scFv to characterize brain tissue from AD mouse models and from post-mortem human 
sources using a sandwich ELISA.  
3.2 Experimental procedure: 
 3.2.1 7PA2 and CHO dot blot. 
 3.2.1.1 7PA2 and CHO cell line maintenance. 7PA2 is a CHO cell line transfected with 
cDNA to over-express mutant human APP751. 7PA2 and CHO cell lines were grown in Dulbecco's 
modified eagle medium (DMEM) with 10% fetal bovine serum, 1% penicillin-stremptomycin and 
1% L-glutamine. Mutant APP751 expressing cells in 7PA2 cell line were selected by using 
1mg/mL of G-418 antibiotic. Once the flask reached 95% confluence, the supernatant was  
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collected and frozen for 24 hours at -80°C. The sample was then freeze dried and the pellet was 
rediluted in 1mL of sterile 1X PBS. The cells were lysed using lysis buffer with 1% triton-X and 
protease inhibitor. The lysed cells were centrifuged at 900rpm for 5 minutes and the cell debris 
was discarded while lysate was kept frozen at -80°C. 
 3.2.1.2 Preparation of synthetic Aβ. Aβ40 was synthesized and purified by HPLC, 
lyophilized and stored as its Trifluoroacetate salt at -20
o
C. The lyophilized powder was 
solubilized in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) at a concentration of 1 mg/mL to avoid 
aggregates. Prior to use, a 200μL aliquot was air dried and the pellet was re-suspended in 
dimethyl-sulfoxide (DMSO). Aβ in DMSO was diluted to final concentration of 50µM in Tris-
HCl buffer for the dot blot assay and co-incubation studies discussed later. 
 3.2.1.3  Dot blot assay for cell derived oligomeric Aβ . The 7PA2 and CHO supernatant 
was spotted on a nitrocellulose membrane blot. Media blank and synthetic Aβ diluted in Tris HCl 
buffer were used as negative and positive control respectively. The blot was air dried before 2% 
milk incubation for 2 hours at RT. The blot was allowed to incubate in anti-Aβ (6E10) antibody 
for 2 hours at RT. It was then transferred to freshly made 1:1000 dilution of goat anti-mouse 
(GAM) secondary antibody for 1hour at RT. The blot was rinsed thrice with 1X PBS after every 
step to get rid of all the non-specific binding and reduce the background noise. DAB substrate 
was added to the blot and developed.  
A duplicate blot with 7PA2 and CHO supernatant and media were spotted onto the nitrocellulose 
membrane along with anti-pLB as positive control. The blot was air dried and incubated in 2% 
milk for 2 hours at RT. It was then transferred to 1:1000 dilution of an anti-c-myc antibody 
(9E10) followed by 1:2000 dilution of GAM. The blot was developed using DAB. 
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 3.2.2 AFM sample preparation. Circular mica discs were used to prepare samples for 
AFM imaging. Different dilutions of the 7PA2 and CHO supernatant were prepared and 10µL 
were deposited on the mica disc. The sample was allowed to incubate for 10 minutes at RT and 
washed with water to get rid of the unbound protein in the sample. This was followed by 
deposition of 10µL of C6T phage deposition. The phage was allowed to incubate on the mica disc 
for 10 minutes at RT followed by stringent washing with PBS-0.1% tween and water to get rid of 
the unbound phage. Excess water was removed and the sample was air dried for 10 minutes and 
20 and 5 micron images were obtained. 
 3.2.3 C6T-Aβ co-incubation. 50µM of synthetic Aβ as prepared previously was 
incubated at 37°C with and without C6T scFv of 5µM concentration. Aliquots of 100µL were 
prepared and were removed at various time intervals of 0, 1 and 4 days from the incubator. 25µL 
of the samples were loaded onto a 10% tris-tricene gel and allowed to separate. One of the gels 
were stained using 0.1% Coomassie brilliant blue dye and the other was used to transfer the 
separated bands onto a 0.2µm nitrocellulose blot. The gel was de-stained in de-staining solution 
and scanned into the system. The western blot was incubated with 2% milk for 2 hours on a 
shaker at RT followed by incubation with 1:1000 dilution of anti-Aβ antibody (6E10) for 2 hours 
at RT. The blot was then incubated with 1:2000 dilution of GAM and finally stained with DAB 
substrate.  
 3.2.4 Mouse tissue dot blot. We used the C6T scFv to characterize brain tissue taken 
from different ages of a triple transgenic AD mouse line (3x-TG) which has mutant presenilin, 
APP and tau transgenes resulting in over-expression of  both Aβ and tau (Oddo et al., 2003).  
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Previous studies have shown that there is progressive increase in Aβ formation with evident Aβ 
plaque deposition observed around 6 months of age in this model. This is followed by tau tangles 
becoming evident around 12 months of age. 
Age (in weeks) Sample Concentration 
(mg/mL) 
Sample Concentration 
(mg/mL) 
10 TG #1 6.4 WT #1 11.1 
22 TG #2 9.4 WT #2 7.7 
28 TG #3 11.2 WT #3 16.3 
Table 3.1: BCA assay on homogenized 3x-TG and WT mice brain samples. Total protein 
concentration in mg/mL. 
We homogenized 3x-TG and wild type mouse brain tissue (provided by Dr. Jon Valla (Barrow 
Neurological Institute) aged 10, 22 and 28 week using homogenization buffer (with 1% protease 
inhibitor) and a bicinchoninic acid (BCA) assay was done to estimate the total protein 
concentration (Table 3.1). A 1µL aliquot of the homogenized tissue was spotted on nitrocellulose. 
The blot was then blocked with 2% milk for 2 hours at room temperature and probed with 
0.3mg/mL of C6T scFv overnight at 4°C with 1X PBS washes after every step. The blot was 
probed with 9E10 primary antibody (Sigma Aldrich) for 2 hours followed by GAM for 1 hour at 
RT. The blot was developed using DAB substrate. 
 3.2.5 C6T sandwich ELISA. ELISA is an immunosorbent assay that allows the 
detection of antigens using antibodies specific for their detection. In this section, we will be 
discussing the use of C6T scFv in the detection of Aβ oligomers in 3x-TG mice brain tissue 
samples. C6T was used as the capture scFv to bind the Aβ oligomers in the tissue samples. H1V2 
is an scFv isolated from a second generation phage display library against Aβ using immunotube  
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panning protocol (Yuan et al, 2005) and essentially binds to all forms of Aβ. Hence H1V2 phage 
was biotinylated and used for detection. Avidin-HRP, which binds to the biotin in the biotinylated 
H1V2 phage was used as the secondary detection antibody (Figure 3.2). The fluorescence was 
recorded using a spectrophotometer.  
 3.2.5.1 C6T scFv capture. In order to determine the binding efficiency of C6T scFv onto 
the high binding ELISA plates, different concentrations of C6T scFv was added to the plate. The 
plate was washed thrice with 1XPBS-0.1% tween.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Sandwich ELISA - C6T scFv coating for oligomeric Aβ detection using biotinylated 
H1V2 phage and avidin-HRP. 
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BCA was carried out and a concentration of 0.3mg/mL of scFv was observed to saturate the plate. 
Hence 0.3mg/mL of C6T scFv was used as coating for the ELISA assay. 
 3.2.5.2 H1V2 phage biotinylation. H1V2 phage, like mentioned earlier has the ability to 
bind to different forms of Aβ. Thus H1V2 phage having a concentration of 1012pfu/mL was 
biotinylated with 20mM and 100mM biotin and passed through a desalting column to remove 
excess biotin. Biotinylation was verified by depositing different dilutions of the 20mM and 
100mM biotinylated H1V2 phage onto ELISA plate. This was followed by blocking the plate 
with 2% milk for 2 hours at 37°C. After rinsing the plate, fluorescent substrate was added to the 
wells and read in spectrophotometer. 
 3.2.5.3 ELISA mice sample preparation. 3x-TG mice brain samples from Dr. Travis 
Dunkley (Tgen) and wild type samples aged 5, 9 and 13 months were tested in the ELISA.  
Age (in months) Sample Concentration 
(mg/mL) 
Sample Concentration 
(mg/mL) 
5 TG #5-1 4.4 WT #5-1 19 
5 TG #5-2 7.5 WT #5-2 11.9 
9  TG #22 2.4 WT #9-1 12.8 
9 TG #23 6.4 WT #9-2 13.1 
9 TG #24 4.3 WT #9-3 17.2 
13 TG #29 10.2 WT #13-1 16.9 
13 TG #30 6.3 WT #13-2 17.2 
13 TG #36 13 WT #13-2 19.6 
Table 3.2: BCA analysis of total protein concentration in mg/mL on homogenized 3x-TG and WT 
mice brain samples. 
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There were 2 samples in the 5 month group and 3 samples each in the 9 and 13 months with age 
matched controls. These samples were homogenized using homogenization buffer with 1:100 
dilution of 100mM phenylmethylsulfonyl fluoride (PMSF) protease inhibitor. A BCA assay on 
the homogenized tissue yielded total protein values as shown in Table 3.2. 
 3.2.5.4 ELISA Human AD-ND sample preparation. Human brain tissue homogenized 
samples were obtained from Mayo Clinic, Florida. There were 6 AD, 9 Parkinson's disease (PD) 
and 5 non-demented (ND) samples that were tested on sandwich ELISA.  
 3.2.5.5 ELISA protocol. In the sandwich ELISA assay, 100µL of C6T scFv of 0.3mg/mL 
was coated onto high binding ELISA plates and allowed to incubate for 1-2 hours at 37°C. The 
plate was washed thrice with 1X PBS-0.1%tween after every step to get rid of any non-specific 
binding to reduce any background noise. The plate was loaded with 200µL of 2% milk for 2 
hours at 37°C for blocking the wells. After rinsing the plate, 100µL of 200µg/mL of 
homogenized (mice/human) sample was incubated for 1 hour at 37°C. This is followed by the 
addition of 100µL of biotinylated H1V2 phage (20mM). The plate was allowed to incubate at 
37°C for one hour and washed 4 times to get rid of any non-specific phage binding. 1:2000 
dilution of avidin-HRP was added to the plate and incubated for 1 hour at 37°C. Fluorescent 
substrate was added in the final step and readings were recorded every 15 minutes in the 
spectrophotometer. 
3.3 Results and Discussion: 
 3.3.1 7PA2 and CHO dot blot assay. 7PA2 is a CHO cell line that over expresses 
mutant APP and Aβ oligomers. In order to characterize C6T and test its specificity to in-vitro 
generated Aβ oligomers, 7PA2 and CHO cell line supernatant was tested with C6T. Concentrated 
supernatant from 7PA2 and CHO cell lines were spotted on nitrocellulose and probed with 6E10,  
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an antibody against monomeric Aβ to verify the presence of Aβ in the 7PA2 supernatant, but not 
the control CHO supernatant or in the media (Fig 3.3). Supernatant and periplasm fractions from 
an E. coli strain expressing the C6T scFv were also spotted on the membrane as negative controls 
and as expected, did not show any reactivity with 6E10. This confirmed the presence of Aβ in 
7PA2 supernatant though it is not known if any of the Aβ present is in different aggregated forms.   
 
 
Figure 3.3: 7PA2 and CHO dot blot developed with 6E10 antibody (1:1000 dil) and GAM 
(1:2000 dil). This dot blow shows the presence of Aβ in 7PA2 supernatant compared to CHO 
supernatant and media controls.  
We also probed the cell line supernatant samples with C6T to verify the presence of oligomeric 
Aβ (Fig 3.4). When probed with C6T the 7PA2 supernatant showed strong reactivity while the 
CHO supernatant sample did not show any reactivity indicating the presence of oligomeric Aβ in 
the 7PA2 culture supernatant. As expected, the C6T control sample had reactivity indicating that 
the reagents used for the assay are reliable. The staining we see in the 7PA2 supernatant is due to 
the scFv binding to oligomeric Aβ in the 7PA2 supernatant indicating C6T's ability to recognize 
in-vitro generated Aβ.       
C6T        7PA2    CHO             
Supernatant  
 
 
 
 
Media 
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Figure 3.4: a) 7PA2 and CHO dot blot incubated with C6T and developed with 9E10 antibody 
and GAM. This dot blow shows C6T' scFv's specific interaction with the 7PA2 supernatant 
compared to CHO supernatant and media controls.  
 3.3.2 AFM Imaging. We further analyzed the 7PA2 and CHO supernatant samples for 
the presence of oligomeric Aβ using AFM. We incubated an aliquot of concentrated supernatant 
sample with a phage-displayed version of the C6T scFv so we could visually image binding of the 
C6T phage to the Aβ oligomers.  The concentrated supernatant contains an array of other proteins 
and salts which show up as large white spots on the AFM images.  Highly concentrated samples 
result in multiple layers that do not provide quality images. Hence several dilutions of the 
supernatant were deposited on cleaved mica surface followed by C6T phage deposition. We could 
clearly observe C6T phage bind to the 7PA2 supernatant sample but not the control CHO 
supernatant (Figure 3.5).  This reconfirms the ability of C6T to specifically recognize oligomeric 
Aβ generated in the 7PA2 cell line.  
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          (a)     7PA2 Supernatant with C6T phage: 
 
           (b)    CHO Supernatant with C6T phage: 
 
Figure 3.5: AFM images of C6T phage with (a) 7PA2 supernatant and (b) CHO supernatant. 
Scale to 5nm. 
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 3.3.3 Aβ-C6T co-incubation. In-vitro generated synthetic Aβ aggregates were allowed to 
incubate for 0, 1 and 4 days either in the presence or absence of C6T scFv. These samples were 
separated on a 10% Tris-tricine gel containing SDS. A strong band corresponding to monomeric 
Aβ was observed in all lanes. This is because in-vitro generated Aβ is not stable and appears as a 
monomeric band when run on tris-tricene gel.  
When the western blot was probed with the anti-Aβ antibody (6E10), low intensity bands 
corresponding to a different Aβ aggregate sizes were observed. This indicates that co-incubation 
with C6T generates SDS-stable oligomers similar to the oligomers generated in vivo. No 
aggregates were seen in the Aβ samples incubated without C6T and in the C6T samples run on 
the western. These results provide further evidence that C6T selectively binds an Aβ species.  It is 
also possible that C6T can bind to these toxic oligomeric Aβ species and prevent them from 
spreading to other cells suggesting a potential therapeutic value of C6T for treating AD  
 
 
Figure 3.6: Western blot of aggregated 50µM Aβ samples in the presence and absence of 5µM 
C6T scFv probed with 6E10 and GAM. 
C6T C6T C6T      M C6T+aβ     C6T+aβ   C6T+aβ     aβ       aβ      aβ  
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 3.3.4 Mouse tissue dot blot. Once the specificity of C6T to in vitro generated oligomeric 
Aβ was established, it was used to characterize AD mouse model of different age groups. Dot 
blot with triple transgenic and wild type (WT) homogenized brain tissue was spotted on a 
nitrocellulose membrane and probed with C6T scFv (Figure 3.7).  
 
 
Figure 3.7: Homogenized brain dot blot of triple transgenic and wild type mice aged 10, 20 and 
28 weeks probed with C6T scFv. 
 
Figure 3.8: Normalized intensity of homogenized mice brain samples on the dot blot using 
ImageJ software. 
10w 20w 28w anti-pLB 
TG 
WT 
38 
 
It can be noted that from Figure 3.8 that the C6T scFv was able to distinguish between the 3x-TG 
and WT samples especially in the 20 week (P<0.0048) and 28 week (P<0.0016) age groups. This 
indicates that the C6T clone is capable of detecting Aβ oligomers much earlier than other 
reagents that detect the presence of Aβ plaques in the brain of these mice. 
 3.3.5 C6T Sandwich ELISA 
 3.3.5.1 C6T scFv capture ELISA. To test the ability of C6T scFv to bind to the ELISA 
plate and be a successful capture scFv for Aβ in tissue samples, different concentrations of C6T 
was deposited onto the plate. After a blocking step, a BCA was carried out to determine the 
concentration of C6T bound to the plate.  
It can be seen from Table 3.3 that the C6T scFv binds to the plate resulting in a signal compared 
to the no scFv negative control. Irrespective of the concentration of scFv deposited, the plate 
saturates around 0.1-0.2mg/mL. Previous ELISA assays indicate that a concentration of 
0.3mg/mL of scFv deposited on the plate generated reliable data. Hence the same concentration 
of C6T scFv was used for the sandwich ELISA. 
C6T Dilution Deposited concentration 
(mg/mL) 
Concentration of C6T on plate 
(mg/mL) 
1 1.3 0.22 
0.5 0.65 0.18 
0.25 0.32 0.12 
0.125 0.16 0.10 
Table 3.3: C6T scFv deposited on ELISA plate to determine optimal concentration to be used in 
ELISA assay. 
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 3.3.5.2 H1V2 phage biotinylation. H1V2 phage was isolated from a second generation 
phage display against Aβ and binds essentially to all forms of Aβ. It was used for detection of Aβ 
oligomers with C6T as the capture scFv. Previous studies with regular H1V2 phage and anti-M13 
detection antibody gave a high background.  
Phage dilution 
(log 10) 
20mM biotin 100mM biotin 
-2 22.12 22.92 
-3 10.69 3.98 
-4 2.29 1.28 
-5 1.12 1.03 
-6 1.09 1.05 
-7 0.98 0.99 
No phage 1 1 
Table 3.4: Different dilutions of H1V2 phage biotinylated with 20mM and 100mM biotin with 
respect to no phage control sample. 
In order to improve the signal to noise ratio, we biotinylated the detection agent, the H1V2 phage 
to increase the signal. Since the phage has about 2700 copies of the phage coat protein p8, 
biotinylation offers an increased signal to noise ratio which is essential for any detection assay. 
Since 20mM and 100mM biotin levels gave similar detection signals, we utilized 20mM biotin to 
label phage for the ELISA (Table 3.4). Using this protocol, a reliable signal can be obtained even 
with phage dilutions of 10
-5
. However for the ELISA reaction 1:100 dilution of the 20mM 
biotinylated phage was used since it gave a high signal compared to the background control.  
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 3.3.5.3 ELISA of AD mouse tissue. Triple transgenic mouse brain tissue samples were 
analyzed using the  sandwich ELISA with age matched wild-type or non-transgenic (NTG) 
controls from the same strain of mice.  
Groups  Significance (P<0.05) 
TG 5 month NTG 5 month 0.000332774 
 NTG 9 month 0.000432506 
 NTG 13 month 0.000288782 
TG 9 month NTG 5 month 0.000353866 
 NTG 9 month 0.000438324 
 NTG 13 month 0.000279134 
TG 13 month NTG 5 month 0.002666807 
 NTG 9 month 0.004388366 
 NTG 13 month 0.002620591 
Table 3.5: One way ANOVA analysis of 3x-TG and non-transgenic (NTG) samples, 30 minutes 
after the addition of fluorescent substrate. 
From Table 3.5, it can be observed that C6T is an excellent reagent to distinguish between the 3x-
TG and non-transgenic (NTG) samples (P<0.0002). Each of the 3x-TG 5, 9 and 13 month 
readings were distinctly higher than the entire NTG control group. Several negative controls 
including no scFv with sample and no scFv without sample were run on the ELISA. All the 
negative control signals were negligible and equivalent to the background.  
It can be seen from Figure 3.9 that there is a decreasing trend in the 3x-TG group with increasing 
age. This is consistent with the Aβ hypothesis that the Aβ oligomers reduce with increasing age 
due to increased amyloid plaque deposition in the brains of these mice. The graph also shows that  
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C6T is ideal for detecting Aβ oligomers earlier on, before the onset of neuropathological 
symptoms in the 3x-TG model. Hence C6T is a promising tool that can be used for early 
detection of AD. 
 
Figure 3.9: ELISA results comparing 3x-TG and NTG over 5, 9 and 13 month homogenized mice 
brain samples using C6T scFv (0.3mg/mL).  
 3.3.5.4 Human ELISA. We also analyzed post-mortem human brain samples with C6T 
to probe for the presence of oligomeric Aβ in AD, PD and healthy non-demented (ND) samples. 
Fluorescence signals obtained were normalized to the background signal and ratios were obtained 
with respect to the no sample control. It can be seen from Table 3.6 that C6T was able to 
distinguish AD samples from the ND and PD samples.  
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Sample Signal-C6T Sample Signal-C6T Sample Signal-C6T 
AD 07-02 ++++ PD 02-15 - ND 02-06 - 
AD 01-22 + PD 00-16 - ND 00-38 - 
AD 00-28 - PD 00-24 + ND 03-39 - 
AD 06-28 + PD 00-27 - ND 03-41 +++ 
AD 00-35 ++++ PD 98-29 ++ ND 04-38 - 
AD 06-48 ++ PD 02-37 +   
  PD 01-38 -   
  PD 00-45 -   
  PD 07-66 -   
Table 3.6: ELISA results on human AD, ND and PD samples. 
C6T showed reactivity with five out of the six AD sample with two samples yielding 
very strong signals.  Three of the nine PD samples also showed reactivity with C6T as 
did one ND sample. Around one third of patients with PD develop some form of 
dementia leading to AD so it is possible that the three PD samples showing reactivity 
with C6T may have AD as well.  The one ND samples that showed reactivity with C6T 
has also showed high reactivity with other oligomeric proteins in our lab and may be due 
pre-symptomatic conditions or an incorrect diagnosis. It can be seen from these results 
that C6T has the potential to be used as an early stage biomarker for AD. 
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Chapter 4 
CONCLUSION 
4.1 Summary: 
Alzheimer's Disease (AD) is a progressive neurodegenerative disease characterized by the 
deposition of extracellular plaques and neurofibrillary tangles. A primary component of these 
plaques is the amyloid-beta (Aβ) protein. It exists as soluble oligomeric Aβ, a synapto-toxic 
species correlating with disease progression in AD (Lesné et al., 2006)(Mclean et al., 1999).  
Current treatment options like cholinesterase inhibitors provide temporary relief to the memory 
loss symptoms observed in AD. Recent studies have shown that it takes 12-15 years for a 
cognitively normal person to deposit considerable Aβ resulting in cognitive impairment 
(Villemagne et al., 2013 and Jack et al., 2013). Thus using an anti-oligomeric Aβ scFv within this 
timeframe will serve as a valuable diagnostic and therapeutic tool.  
C6T scFv was isolated from a phage display library against human brain derived oligomeric Aβ 
(Kasturirangan et al., 2013). The frameshift mutation upstream of the sequence was corrected 
using specific PCR primers to insert the missing nucleotide. The corrected C6T clone showed 
increased production compared to the old C6. Specificity of the C6T clone was verified using 
7PA2 cell line that over expresses mutant APP and Aβ oligomers with CHO as a control. 
Triple transgenic AD mice that over express mutant APP and Aβ oligomers and wild type mice of 
different age groups, were characterized using C6T. A series of dot blots, and ELISAs showed 
that the C6T was able to distinguish the transgenic AD mice samples from WT.  C6T was also 
able to differentiate between AD, PD and healthy human post-mortem samples using sandwich 
ELISA. These characterization studies show that C6T has the potential to be used as a diagnostic 
tool for early detection of AD. We intend to use our array of scFvs (against different forms of Aβ) 
on these AD samples to determine disease progression as well as distinguish it from healthy, non-
demented samples.  
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4.2 Future work:  
Based on the results discussed in this thesis, future work includes:  
1. Co-localization studies: To study how C6T interacts with oligomeric Aβ in 7PA2 cells 
and to visualize its extracellular co-localization by fluorescently labeling both C6T scFv 
and oligomeric Aβ.  
2. Toxicity study of C6T clone: In order to characterize C6T better, a lactate dehydrogenase 
assay (LDH) can be carried out on SHY-5Y cells. Aggregated Aβ either with or without 
the C6T scFv can be added to measure the cytotoxicity.  
3. Construction of bi-specific diabodies: C6T scFv can be attached in tandem to another 
proteolytic scFv to generate a diabody that will target specific forms of oligomeric Aβ 
and clear them.  
4. Targeting scFv to the brain: Once the C6T clone is completely characterized, several 
methods like viral vector delivery, peptide tags can be used to test its ability to cross the 
blood-brain-barrier in an appropriate model. However extensive studies need to be 
carried out prior to testing.  
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